ENZN
Viskase Holdings, Inc.
Key Financials
Gross Profit
$20.1M
N/A
Operating Income
$-5311000
↓ 300.2%
Revenue
$176.7M
N/A
Net Income
$-3409000
↓ 538.2%
EPS (Diluted)
$-0.07
↓ 600.0%
Total Liabilities
$4.8M
↓ 11.7%
Cash & Equivalents
$42.6M
↓ 9.1%
Total Assets
$42.8M
↓ 9.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/3/2026 | View on SEC |
| 8-A12G | 5/5/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| 10-Q | 5/4/2026 | View on SEC |
| 3 | 5/1/2026 | View on SEC |
| 8-K/A | 5/1/2026 | View on SEC |
| 8-K | 5/1/2026 | View on SEC |
| 10-K/A | 4/29/2026 | View on SEC |
| 8-K | 4/21/2026 | View on SEC |
| 8-K | 4/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ENZN |
| Company Name | Viskase Holdings, Inc. |
| CIK | 727510 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (630) 874-0700 |